Oncolys BioPharmaOncolys BioPharma Inc.4588東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP

Oncolys BioPharma FY ending Dec 2019 results

About 99% of Oncolys BioPharma's sales come from Pharmaceutical Division, with Diagnostic Division making up much of the rest.

It lost about ¥39 for every ¥100 of sales at the operating level.

Where the money goes

For every ¥100 Oncolys BioPharma sells, how much goes where, and how much is kept.

FY ending Dec 2019

Margin funnel (derived from reported values)Gross margin 91.3% → Operating margin -39.2% → Net margin -70.0%

Revenue by business segment, and the profit each one keeps.

FY ending Dec 2019

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第20期(2023/01/01－2023/12/31)
ID S100T65H2024-03-29Open
EDINET (FSA Japan)
訂正有価証券報告書－第18期(令和3年1月1日－令和3年12月31日)
ID S100PNC22022-11-17Open
EDINET (FSA Japan)
有価証券報告書－第17期(令和2年1月1日－令和2年12月31日)
ID S100L1LQ2021-03-26Open

Extracted from XBRL: 35 / Derived from other figures: 2

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.